ENTA Enanta Pharmaceuticals Inc
814
$12.65
$0.28
(2.17%)
| Watchers | 814 |
| 52-Wk Low | $8.08 |
| 52-Wk High | $28.25 |
| Market Cap | $273.55M |
| Volume | 110,077.00 |
| 52-Wk High | $28.25 |
| 52-Wk Low | $8.08 |
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences ConferenceBusiness Wire • 4 days ago
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R...
Share to Feed
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment...
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given an average recommendation of "Hold" by the six ratings firms that are presently covering the stock, MarketBeat.com reports...
StockNews.com upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA - Free Report) from a sell rating to a hold rating in a research report released on Friday morning. Separately, JPMorgan Chase...
Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) was upgraded by equities researchers at StockNews.com from a "sell" rating to a "hold" rating in a note issued to investors on...
This price move could be a signal that ENTA may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA Get Free Report) have received an average recommendation of Hold from the six analysts that are covering the firm...